GlassScriptPhysician profile
Halie M Anderson
NPI 1659669984
$3,059.06
in general payments reported to CMS, 2019-2025
18 companies · $1,146 in 2025
The $1,146 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $30.13 · 2021: $140 · 2022: $434 · 2023: $468 · 2024: $632 · 2025: $1,146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,986 · Education: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,985.54 |
| Education | $260.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $655.88 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $546.81 | 2019-2025 | |
| Glaxosmithkline, LLC. | $404.72 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Pharming Healthcare, INC. | $241.61 | 2021-2025 | Joenja, Ruconest |
| Csl Behring | $210.84 | 2024-2025 | Hizentra, Andembry, Haegarda |
| Genentech USA, INC. | $200.15 | 2021-2025 | Xolair |
| Sanofi-Aventis U.S. LLC | $199.94 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $157.93 | 2020-2025 | Cuvitru, Takhzyro |
| Regeneron Healthcare Solutions, INC. | $154.54 | 2021-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $84.30 | 2019-2025 | |
| Amgen INC. | $59.70 | 2024 | Tezspire, Actimmune |
| Horizon Therapeutics Plc | $33.95 | 2019-2021 | |
| Ars Pharmaceuticals Operations, INC. | $31.45 | 2025 | Neffy |
| Lilly USA, LLC | $18.80 | 2025 | Taltz, Ebglyss |
| Galderma Laboratories, L.P. | $16.85 | 2025 | Nemluvio |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $14.70 | 2023 | Orladeyo |
| Shire North American Group INC | $14.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.89 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Halie Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.